Navigation Links
Silence Therapeutics Patent Update
Date:7/30/2008

ed to commercialize the truly novel delivery systems that the two partners develop together.

In July 2007, Silence Therapeutics formed its first research and development collaboration with AstraZeneca to develop novel AtuRNAi therapeutics against five specific targets, including those in respiratory indications. This collaboration was the first industry validation of the potential application of Silence Therapeutics' proprietary AtuRNAi molecules and solidified the Company's leadership position in field of RNAi therapeutics.

The Company's AtuRNAi technology also has been sublicensed to Pfizer via Quark's license to them of the compound RTP-801i-14 for the treatment of age-related macular degeneration (AMD) and a number of other indications. This compound entered the clinic in early 2007. Silence Therapeutics also has licensed to Quark rights to the AtuRNAi structure for Quark's proprietary compound, AKIi-5, which is in a Phase I human clinical study for treatment of acute kidney injury.

Silence Therapeutics is based in London, UK, and Berlin, Germany, and is listed on AIM.

About RNAi

RNA interference (RNAi), is a Nobel Prize winning technology and one of the most exciting areas of drug discovery today. It represents a completely new approach to selectively 'silence' or inactivate disease relevant genes and as such it has the potential to create a new class of therapeutic products. RNAi could therefore offer a therapeutic approach to a broad range of diseases (cancer, infectious diseases, inherited diseases), many of which have been regarded as incurable and are not addressed by current therapeutics, therefore providing a large market opportunity.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027
2. Organizational Changes at Silence Therapeutics
3. Silence Therapeutics Announces Successful Opposition of Glover Patent
4. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
5. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
6. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
7. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
8. Cara Therapeutics Secures $12.3 Million in Series C Extension Financing
9. United Therapeutics to Announce Second Quarter 2008 Financial Results Before Market Open on Thursday, July 31, 2008
10. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
11. Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... York (PRWEB) March 27, 2015 Governor ... 2015 application period for 43North - the world’s largest ... including a grand prize of $1 million, six $500,000 ... from around the world to compete for prizes that ... enterprises in the Western New York region. , ...
(Date:3/26/2015)... San Bruno, CA (PRWEB) March 26, 2015 ... organization (CRO), announced today several management and executive ... role of Chief Financial Officer (CFO) and member of ... Vice President of Business Operations, and Sue Dowden will ... Tony Taricco, co-founder and current Chief Operations Officer (COO), ...
(Date:3/26/2015)... The Market Element LLC, a leading ... with Designing Gig LLC to provide website design, development, ... “Forging this alliance with Designing Gig represents a pivotal ... a comprehensive, end-to-end, digital solution for our clients, which ... Chuck Miller, president of The Market Element. “For small ...
(Date:3/26/2015)... and CINCINNATI , March 26, ... SHP, NASDAQ: SHPG ) and Cincinnati Children,s ... research collaboration for rare diseases. The goal of the ... to treat rare diseases with high unmet medical ... Cincinnati Children,s research expertise. As a nationally ranked ...
Breaking Biology Technology:Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 4Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 5PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5
... N.C. A genetic tool used by medical researchers may ... microbes and viruses from drinking water. , In a series ... of genetic material could successfully target a matching portion of ... make it stop working. If this new approach can be ...
... - YM BioSciences Inc.,(AMEX: YMI , TSX: ... and commercializes differentiated products for patients worldwide,today announced ... its,anti-cancer drug nimotuzumab, a humanized monoclonal antibody that ... the 2008 American,Society of Clinical Oncology (ASCO) Annual ...
... presentation at the 14th,International Conference on Prenatal Diagnosis and ... Diagnostic.,I.D.Rh(D) is the first in a series of noninvasive ... maternal blood sample., The I.D.Rh(D) test diagnoses the ... and can be performed as early as ten weeks ...
Cached Biology Technology:Possible new approach to purifying drinking water 2Possible new approach to purifying drinking water 3NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING 2NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING 3NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING 4Presentation at the 14th International Conference on Prenatal Diagnosis and Therapy Highlights Biocept's I.D.Rh(D) Prenatal Diagnostic 2
(Date:3/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) ... Global Strategic Business Report" report to their offering. ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... Latin America . Annual estimates and ...
(Date:3/17/2015)... 17, 2015  MecklerMedia Corporation (OTCQX: MECK) announced ... service robots ever held in New ... May 11-13, 2015 at the Javits Convention Center. ... event include: Acorn Product Development; Axis NJ; c-Link ... Robotics; Littler; NewBotic Corporation; Neya Systems LLC; Reliabotics; ...
(Date:3/12/2015)... , March 12, 2015 WHEN:Tuesday, March ... Registration here: http://bit.ly/1G7Os0L . SPEAKERS: , Frost ... SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 Biometric ... to compete in several different markets and industries. ... currently witnessing an uptrend. Join ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... be brought back from the brink with help from ... Kerrie Mengersen, from the School of Mathematical Sciences, is ... the Indonesian primate whose name means "person of the ... a quarter of villagers who lived side-by-side with orangutans ...
... /PRNewswire/ -- PAREXEL International Corporation ... services provider, today announced that it reached a milestone ... during the past three years.  The studies, which were ... more than 3,000 patients.   Early phase studies conducted ...
... results from a study by neuroscientists at Rush University Medical ... exhibit a specific structural change in the brain that can ... identify those who would most benefit from early intervention. ... meeting for the Society of Neuroscience in San Diego, Calif., ...
Cached Biology News:Orangutans count on stats for survival 2PAREXEL Completes 200 Patient Studies In Its Early Phase Units Over Three Years 2PAREXEL Completes 200 Patient Studies In Its Early Phase Units Over Three Years 3PAREXEL Completes 200 Patient Studies In Its Early Phase Units Over Three Years 4MRI scans show structural brain changes in people at risk for Alzheimer's disease 2
E2F-5...
DAP12 Market Segment: Protein Kinases...
Rabbit polyclonal to Flagellin ( Abpromise for all tested applications). Antigen: Synthetic peptide from the flagellin C terminal domain of Burkholderia pseudomallei....
Naphthol Blue Black, CI 20470...
Biology Products: